Pallas vs Embody: GLP-1 Telehealth Compared

Embody (joinem.co) advertises some of the lowest compounded GLP-1 prices anywhere — semaglutide from $79/month with a price-for-life pledge. Pallas Health's numbers are higher, and published differently: the whole arc — intro, renewal, interval — in one sentence, from a platform whose certification you can verify. That's the real shape of this comparison: a very low advertised number from a very young company, versus published terms you can check.

This is an honest comparison. Pricing on both sides changes often — Embody's ad funnels show different numbers than its main site — so figures reflect its main site as published in August 2026. Confirm current numbers on both sites before signing up.

The three differences that matter most

1. The advertised number. Embody's main site lists compounded semaglutide "starting at $79/month" and tirzepatide at $129/month, flat at every dose per its price-for-life pledge, with no membership and free 1–2 day shipping. Those numbers are lower than Pallas's — plainly. Pallas's compounded semaglutide injection is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. Tirzepatide is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. With any deeply promotional price, confirm in writing what your renewal will be — Embody's own pledge is the right thing to hold it to.
2. The paperwork. Embody's site currently gives two different cancellation notice windows — its refund policy says 72 hours before billing, its terms say 5 days before the end of your prescription period — and it advertises a satisfaction guarantee whose terms don't appear in its published refund policy. None of that makes the offer false; it does mean you should get the operative terms in writing before you pay. Pallas has one set of terms: cancel anytime, no notice window, full refund if a clinician doesn't prescribe.
3. Track record and tiers. Embody's operating entity started in late 2025 and offers compounded injections only. Pallas is also young (2026) — the difference is verifiability and breadth: LegitScript Healthcare Merchant Certification checkable in LegitScript's public database, published clinical leadership, and both tiers, with FDA-approved brands dispensed cash-pay from $1,069/month.

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.

Quick comparison

What Embody does well

The lowest main-site prices in the category. $79/month semaglutide and $129/month tirzepatide — flat at every dose per its pledge, with no membership and fast free shipping — undercut essentially every established platform, Pallas included. It refunds in full if a clinician doesn't prescribe, and it names its 503A compounding pharmacy partners on its site, a transparency point in its favor.

What Pallas does differently

Terms that match their marketing. One published price arc — $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. — one cancellation policy (anytime, no window), one refund promise (full, if not prescribed), no discrepancies to reconcile. What Pallas advertises is what its terms say.

Both tiers. If a brand-name medication becomes the right fit, Pallas dispenses Wegovy®, Ozempic®, Zepbound®, and Mounjaro® cash-pay with no membership — Embody can't prescribe them at all.

Verifiability. LegitScript Healthcare Merchant Certification you can confirm in LegitScript's public database, published clinical leadership, Louisiana and DC served, and a self-serve portal with anytime provider messaging plus the free Pallas companion app (iOS and Android). Whatever platform you consider, run the same checks: LegitScript status, clinician licensure in your state, US-licensed pharmacy sourcing — and the renewal price in writing.

Who should pick which

Embody may fit if:

• Its price is the deciding factor and you've confirmed the renewal rate and the operative cancellation terms in writing
• You only want compounded therapy and live outside Louisiana

Pallas is probably the better fit if:

• You want published, internally consistent terms and a verifiable certification
• You may want brand-name medication now or later
• You want cancel-anytime flexibility with no notice window and no order lock beyond the not-prescribed refund
• You live in Louisiana or DC, or you'd use the free companion app

Switching between them

Bring your medication name, current dose, and titration history. Time an Embody exit around whichever notice window it confirms for you in writing. A Pallas clinician picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.

References

Platform pricing and program details reflect each company's publicly published terms as of August 2026 and change frequently — confirm current numbers on each platform's site before enrolling. The regulatory basis for compounded preparations is summarized by the FDA.

1. Embody. Pricing, refund policy, and terms, as published August 2026.
2. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. 2025.

Bottom line: Embody's advertised prices are the lowest on the board, from a company operating since late 2025 with internally inconsistent cancellation terms and a guarantee whose conditions aren't published. Pallas costs more per month and publishes everything: the full price arc, one cancellation policy, a full refund if a clinician doesn't prescribe, brand-name access, and certification you can verify. If price alone decides it, hold Embody to its pledge in writing; if published terms decide it, that's what Pallas is built on.